FDA fast track status for Zika Vaccine

Takeda has been awarded fast track status for their vaccine for treatment of the Zika virus. Currently, there are no approved vaccines or drugs against the infection, which can cause microcephaly and other congenital brain abnormalities in infants born to infected mothers. For Takeda, the designation means more frequent interactions with the agency and eligibility for accelerated approval and a priority review.

Click here to view the entire article.